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ABSTRACT the structure of the influenza virus neuraminidases, the spatial organization of their active site, the mechanism of carbohydrate chains desialylation by 
neuraminidase, and its role in the influenza virus function at different stages of the viral infectious cycle are considered in this review. Data on the neuraminidase 
substrate specificity and different approaches in studying the activity of this enzyme are summarized. In addition, data on neuraminidase inhibitors (as antivirals) 
are provided, along with considerations on the mechanisms of resistance of modern influenza viruses to those antivirals.
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Abbreviations: a.a. – amino acid residue; HA – haemagglutinin; nA – neuraminidase; neu5Ac − n-acetylneuraminic acid; 3`SiaLac –  neuAcα2-3Galβ1-4Glc; 
6`SiaLac – neuAcα2-6Galβ1-4Glc; Mu-nAnA – methylumbelliferyl-α-neuraminic acid; BODIPY - 6-((4,4-difluoro-5,7- dimethyl -4- bora -3a,4a-diaza-s-
indacene-3-propionyl)amino)-hexaonic acid, succinimidyl ester; MDcK – Madin-Darby canine Kidney cells; VerO – kidney epithelial cells from African green 
monkey ; neu5Gc – n-glycolylneuraminic acid; 3`SiaLacnAc – neu5Acα2-3Galβ1-4GlcnAc; 6`SiaLacnAc – neu5Acα2-6Galβ1-4GlcnAc.
t
he influenza virus is an enveloped (-)rnA contain-
ing a virus with a segmented genome, and its genetic 
material is coded by eight rnA-segments. All rnA 
segments are packed in a nucleocapsid protein, and a complex 
of polymerase proteins is attached to each of the genomic seg-
ments. those rnA-protein complexes are packed in a lipo-
protein envelope lined from the inside with a matrix protein, 
with haemagglutinin, neuraminidase, and M2 proteins ex-
posed on the outer surface of the viral particle. 
neuraminidase is an exosialidase (ec 3.2.1.18) which 
cleaves α-ketosidic linkage between the sialic (n-acetyl-
neuraminic) acid and an adjacent sugar residue [1]. the amino 
acid sequence of nA is coded by the 6th rnA segment. nine 
subtypes of nA are described for influenza A, whereas only 
one nA subtype was revealed for the influenza viruses B and 
c [2]. nine subtypes of influenza A nA are divided into two 
phylogenic groups. the first group consists of the neuramini-
dases of n1, n4, n5 and n8 subtypes, and the second one con-
sists of n2, n3, n6 n7 and n9 subtypes [3].
the enzyme of the influenza c virus does not belong to the 
neuraminidase group. It promotes the O-deacetylation of the 
n-acetyl-9-O-acetylneuraminic acid, i.e. it belongs to the es-
terase family and will not be considered in this review. 
the influenza virus nA executes several functions. Firstly, 
its activity is required at the time of the budding of newly 
formed viral particles from the surface of the infected cell, to 
prevent aggregation of viral particles. In addition, nA cleaves 
neuraminic acid residues from the respiratory tract mucins; 
by doing so, it facilitates viral movement to the target cell. 
those functions will be considered further in more detail. 
NEuRAMINIDASE STuRCTuRE
the polypeptide chain of the influenza virus nA comprises 
470 amino acid residues. the three-dimensional structure of 
nA consists of several domains: the cytoplasmic, transmem-
brane, “head,” and also “stem,” connecting the head to the 
transmembrane domain. 
On the virion surface, nA resembles a homotetramer of a 
mushroom shape: head of 80*80*40 Å on the thin stem, 15 Å 
wide and from 60 to 100 Å long [2]. the molecular mass of the 
monomer is ≈ 60 kDa, and ≈ 240 kDa for the tetramer [1]. One 
viral particle has approximately 50 tetramers. tetramers can 
form clusters on the viral surface [4]. the three-dimensional 
structure has been revealed for n1, n2, n4, n8, n9 and В nA 
[1, 3, 5, 6, 7]. notwithstanding that nA types A and B homol-
ogy cover only 30 %, their three-dimensional structures are 
virtually identical [6]. 
hEAD
the enzyme active site and calcium binding domain, which 
stabilizes the enzyme structure at low pH values, are situated 
in the head of nA [2; 8]. 
Homology between the strains inside one subtype attains 
about 90%, whereas homology between subtypes is 50%, and 
30% between А and В types [9]. A.a. region 74-390 is the most 
conservative (n2 numbering)1. residues, which account for 
the catalytic function of the enzyme (Arg118, Asp151, Arg152, 
Arg224, Glu276, Arg292, Arg371 and tyr406, Figure 1), are 
constant for all nA subtypes of influenza A and also for in-
fluenza B nA. this works also for amino acids, which form 
the dimensional structure of the active site: Glu119, Arg156, 
trp178, Ser179, Asp198, Ile222, Glu227, Glu277, Asp293, and 
Glu425. Asparagine residues, which form the glycosylation 
site, are strictly conservative (specifically, Asn146); proline 
and cysteine residues, which provide the required folding of 
the polypeptide chain and stabilize the 3-dimentional struc-
ture of the molecule, are also quite conservative [2].
the calcium binding site, which is located inside the mol-
ecule (particularly under the active site, if it is placed in ac-
cordance with the picture provided) is formed by the oxygen 
1 As amino acid sequences of different neuraminidases differ from one 
another by insertions and deletions, it is common practice to highlight NA 
subtype according to which the numbering of amino acids is done, usually, 
as in this case N2 subtype numbering is used.reVIeWS
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of the main chain residues 297, 345 and 348, as well as by the 
oxygen of the side chain of Asp324 [1, 6]. Additionally, this 
site is formed by a.a. 293, 347, 111-115 and 139-143 [8].
the second neuraminic acid binding site, the so called HB-
site, was found in n9 neuraminidases [10]. the a.a. sequence 
of this site is highly conservative among avian influenza vi-
ruses. this site is formed by three nA loops:
367 − 372, which is involved in neuraminic acid binding via 
serine residues 367, 370 and 372;
400 − 403, which interacts with the substrate via the side 
chain of asparagine 400, the carbonyl oxygen of the main 
chain of asparagines, and tryptophan 403;
430 – 433, which interacts with neuraminic acid via the 
ε-amino group of lysine 432. 
All six above-mentioned conservative amino acids were 
found only in n9 nA. Avian influenza virus nAs of other 
subtypes usually lack lysine 432, but its absence does not 
interfere with their haemoadsorption activity. Human in-
fluenza virus neuraminidases usually lack the HB-site a.a. 
sequence. At the same time, two early isolates of human in-
fluenza viruses of the Н2n2 subtype (rI+/57 and A/Lenin-
grad/134/57) have the HB-site “frame” (serine triplet and 
tryptophan) [10, 11], which might be indicative of elimination 
of this site in the course of the influenza virus adaptation to 
replication in humans.
the function of the HB-site has yet to be clarified. It 
has been suggested that it may play the role of an alterna-
tive neuraminic acid binding site, in other words, function 
as a surrogate of the influenza virus HA; this assumption is 
based on the existence of viruses with combined HA and nA 
functions in one protein molecule, such as the nD virus. the 
HB-site, described earlier, is common for the nAs of viruses 
which HA interacts with α2-3-sialylated carbohydrate chains 
(i.e. avian and equine influenza viruses); at the same time, the 
key amino acid positions of this site are changed in viruses 
with α2-6-specificity (human, swine, and poultry H9n2 vi-
ruses). It is worth mentioning that the H9n2 influenza viruses 
isolated from poultry in Hong Kong and viruses of H2n2 and 
H3n2 subtypes, which caused human pandemics, have simi-
lar changes in the HB-site sequence. this data allows one to 
suggest that some species of poultry may act as intermediate 
hosts in the influenza virus transfer from its natural reservoir 
(waterfowl population) to humans [11].
ThREE-DIMENSIONAL STRuCTuRE 
the three-dimensional structure of cytoplasmic, transmem-
brane and stem domains has not been determined yet (due to 
the features of the enzymes, which are used for cleavage of 
this membrane protein from the virion, the crystallized re-
gion starts at residues ~74-77) [6]. there is speculation about 
the presence of an α-helix motif in the uncrystallized struc-
ture, which has been supported by cryoelectron microscopy 
[4]. therefore, one can unequivocally judge only the chain 
folding of the head region of the enzyme (as part of the te-
trameric structure). the nA’s head region consists of one big 
domain, which is formed by six identical antiparallel β-sheets 
(motifs) organized in the form of a propeller-like structure. 
Loops connecting the motifs and loops between every sec-
ond and third strain of each motif are of ultimate importance 
for the enzyme [2]. Loops are the most variable parts of the 
structure of all nAs; they vary in length and can even have 
some arranged elements typical of the secondary structure. 
For example, loops of n9 nA have some α-helix regions: resi-
dues 106 – 110 form one spiral turn (α), located above the 
С-terminus of the polypeptide chain, which consecutively 
forms another α-helix turn, and a.a. 144 – 146 of the neigh-
boring subunit forms the (310) helix. the 310 helix and two 
chains (106 − 110 and c-terminus) form the antiparallel layer 
[6]. the loop connecting the fourth and the fifth motifs is the 
longest one and is stabilized by a disulfide bridge located be-
tween cys318 and cys337; it also has the conservative ion 
pair Asp330-Arg364 and the ca2+ binding site [1].
gLYCOSYLATION
carbohydrate chains are attached to Asn residues located in 
the different regions of the nA’s head. In particular, glycans 
attached to asparagines 86 and 234 are headed towards the 
lipid membrane close to the stem; those attached to Asn146 – 
are headed from the membrane and are located in close prox-
imity to the active site; finally, glycosylation Asn200 is located 
on the side surface in the region of the subunits contact. Short 
oligomannose type chains were found at residues Asn86 and 
Asn200. carbohydrate chains of a complex type are attached to 
Asn146 and Asn234. the glycosylation site at Asn146 is conser-
vative for all nAs, and this carbohydrate chain differs from all 
other carbohydrates found in all influenza virus glycoproteins: 
it carries the О-4 sulfated n-acetylgalactosamine [1]. Asn146 
glycosylation seems to have a regulatory function, because 
it is known that the lack of this glycosylation site determines 
the influenza virus А/WSn/33 (Н1n1) neurovirulence. It has 
been shown that the carbohydrate chain at Asn146 affects nA 
enzymatic activity, causing a 20-fold decrease in activity [12]. 
Deletion of the glycosylation site at a.a. 144 of n8 nA (А/duck/
Figure 1. Active site of influenza virus A neuraminidase (N2 subtype) in 
complex with Neu5Ac2en (2-deoxy-2,3-didehydro-N-acetylneuraminic 
acid). Neu5Ac2en is presented in black, functional a.a. of the active 
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ukraine/1/63) causes changes in its substrate specificity pro-
file nA [13], and absence of glycosylation sites at a.a. 83 and 398 
causes incorrect molecule folding. 
DISuLFIDE BONDS
there are eight conservative disulfide bonds in the nA struc-
ture, and one additional bond in the n2, n8, and n9 subtypes. 
the invariance of disulfide bonds confirms their importance 
in the formation of a stable nA structure. It is assumed that, 
because of its proximity to the symmetry axis of the tetramer, 
the uncoupled cys161 of n1 nA takes part in the coupling of 
subunits. the tetramer assembly mechanism is not universal: 
for instance, in influenza virus B neuraminidases disulfide 
bonds are formed by cys54, whereas cys78 takes part in 
polypeptide chains binding (n2 numbering) [2].
ACTIVE SITE STRuCTuRE 
the neu5Ac binding site is located above the first strands of 
the third and the fourth motifs in a big loop on the nA sur-
face. the active site is located at the n-terminal end of central 
parallel strands [2]; (Fig.1). It is a cavity 16Å in diameter and 
8 to 10Å in depth, located 32Å from the tetragonal axis. this 
site is surrounded by twelve flexible loops, which go upwards 
from that axis [6]. 
the enzyme active site consists of functional amino acid 
residues Arg118, Asp151, Arg152, Arg224, Glu276, Arg292, 
Arg371, and tyr406, and structural amino acid residues 
Glu119, Arg156, trp178, Ser179, Asp (or Asn in n7 and n9) 
198, Ile222, Glu227, Glu277, Asp293, and Glu425.
Functional a.a. are in direct contact with sialic acid, the 
product of the enzymatic reaction, and they all form polar 
contacts with it, excluding Arg224, whose aliphatic part 
forms a nonpolar contact with the glycerol fragment of the 
neu5Ac residue [9] (Fig.1).
recent X-ray studies of neuraminidases from the first 
phylogenic group have shown that, in comparison with neu-
raminidases from the second phylogenic group, they have a 
slightly different structure of the polypeptide chain around 
the enzyme active centre. In particular, there is a cavity in 
close proximity to the active site, which is formed by a change 
in the dimensional orientation of “loop 150.” these structural 
differences allow the launch of the development of influenza 
virus nA inhibitors, which would specifically interact only 
with nAs of the first phylogenic group, in particular with the 
nA of influenza viruses of the H5n1 subtype [3].
REACTION MEChANISM
the nA’s reaction mechanism (Scheme 1) was proposed 
based on the results of structural studies of the crystallized 
protein [7]. 
Formation of the oxocarbonium ion at the С2 atom of 
neu5Ac is the key step in the hydrolysis of the oligosaccha-
ride substrate. After the introduction of the neu5Ac residue 
into the active centre, neu5Ac conformation changes from 
chair to half-chair, i.e. the oxocarbonium ion is formed, due 
to strong ionic interactions between the carboxylate of the 
substrate and the guanidine groups of the arginines 118, 292 
and 371, eventually leading to glycosidic bond cleavage. the 
molecule of aglycone leaves the enzyme active site with gly-
cosidic oxygen, protonated by the solvent. Multiple contacts 
between the intermediate product and the a.a. of the active 
site (tyr406 and Asp151 are of minor importance) stabilize 
the positively charged oxocarbonium ion with preserva-
tion of the planar carbon at С2. neu5Ac2en, in which the 
c2 atom is in sp2-form, mimics the intermediate reaction 
product in planar conformation [6]. At this stage of the reac-
tion, the neuraminic acid residue is covalently bound to the 
hydroxyl group of tyr406, which is characteristic of all exo-
sialidases [15, 17]. Hydroxylation of the oxocarbonium ion 
with the solvent and product leaving the enzyme active site 
in the form of neu5Ac are the limiting stages of the catalytic 
reaction. It is worth mentioning that there are no significant 
changes in the coordinates of the nA active site during the 
reaction [18].
the presence of invariant residues in the active site, the 
similarity of the structural organization, and the architecture 
of complexes with neu5Ac and with neu5Ac2en allow to as-
sume that the mechanism of nA functioning for the A and B 
influenza viruses is identical [6]. 
NEuRAMINIDASE INhIBITORS AND MEChANISM 
OF ANI-DRug RESISTANCE 
the structure of the neuraminidase active site is strictly con-
servative not only between subtypes, but also between the 
types of the enzyme, which points to the importance of all its 
components and the evolutionary stabilized functioning of 
this system. this observation has allowed to design  an nA 
inhibitor for the influenza virus which mimics the transi-
tion state of the hydrolysis reaction, and neu5Ac2en (Fig.2а), 
4-guanidino-neu5Ac2en, which is now widely used under the 
trade name zanamivir [14] (Fig. 2b). 
the success of this drug has initiated a number of studies 
aimed at designing new nA inhibitors. the main structural 
elements of the new class of inhibitors (without the oxygen 
atom in the cycle) are cyclohexane and cyclopentane. 
One of those structures is the (3S,4r,5r)-3-amino-4-
acetamido-5-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic 
acid (oseltamivir or tamiflu) (Fig. 2c). the structure of this 
molecule is adjusted to coordinates of the amino acids, which 
interact with the glycerol chain of neu5Ac2en [20]. Successful 
use of this drug has stimulated the development of new nA 
inhibitors with hydrophobic groups [21].
Besides, a nA inhibitor on the base of a cyclopentane struc-
ture has been developed; it has all the functionally important 
parts of zanamivir (carboxyl, acetamide, c4-hydroxyl) which 
fit into the nA active centre. BcX-1812 (preamivir) (Fig. 2d) 
retains its activity towards zanamivir-resistant influenza vi-
ruses [22, 23]. At present, preamivir analogs are at the devel-
opment stage.
Zanamivir and oseltamivir are already used as drug prod-
ucts, whereas BcX-1812 has entered the last phase of clinical 
trials. 
until recently, it was considered that active uncontrolled 
use of zanamivir and oseltamivir would not have a signifi-
cant influence on the development of resistance in influenza 
virus strains. that is, even if resistant strains emerge, they 
would not be able to replicate in the absence of the inhibitor 
[24]. the number of resistant viruses isolated in clinical trials 
accounted for less than 1%, same as their presence among 
seasonal influenza virus isolates worldwide. reVIeWS
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However, in January 2008 this situation changed dramati-
cally: some H1n1 influenza viruses developed resistance to 
oseltamivir due to a mutation His274tyr in nA [25], and in 
the epidemic season of 2008-2009 resistance was up to 100% 
among viral isolates (according to http://ecdc.europa.eu); it is 
typical that those isolates preserved sensitivity to zanamivir. 
the mutation His274tyr had been spotted in studies of re-
sistance in vitro and in vivo, as well as in clinical isolates [26]. 
nevertheless, it is still too early to stop usage of this drug, 
because according to the most recent data, the prepandemic 
influenza virus of the H1n1 subtype (A/california/11/2009), 
which is encountered at the moment in humans, is still sus-
ceptible to oseltamivir (according to data from the center for 
Disease control and Prevention, uSA (www.cdc.gov). this 
leaves us with hope that the strain of the influenza virus that 
will cause the next pandemic might be susceptible to this nA 
inhibitor.
NA FuNCTIONAL ACTIVITY
there is data indicating that nA is relevant at different stag-
es of infection. Firstly, it is considered that it helps the vi-
rus approach the target cells by cleavage of sialic acids from 
respiratory tract mucins [26]. Secondly, it may take part in 
the fusion of viral and cell membranes [27]. thirdly, it facili-
tates budding of new virions by preventing their aggregation, 
caused by the interaction of the HA of the first virus with the 
sialylated glycans of the second one [27]. In addition, there is 
data suggesting that nA amplifies HA haemagglutinating 
activity by cleavage of the terminal neuraminic acid residues 
of the oligosaccharides surrounding the receptor-binding site 
of HA [28]. 
One of the most interesting features of the influenza vi-
rus is the coexistence of two proteins whose functions are to 
some extent contradictory, namely: haemagglutinin, which 
has a receptor-binding function; and neuraminidase, which 
has a receptor destroying function. Since both of these pro-
teins recognize terminal neuraminic acid residue, this brings 
up the question of their cooperation or, on the contrary, their 
competition for receptor/substrate, and of the role of their 
relations in viral life cycle. Studies of the viruses resistant to 
nA inhibitors, artificial viral reassortants (which have HA 
and nA of different origins), and virus particles designed by 
means of reverse genetics, which lack nA or HA activity, 
show that the nA and HA of the influenza virus act in con-
cert and their evolution proceeds interdependently [29-35]. 
Also, it raises a question as to their oligosaccharide specificity, 
because neu5Ac-terminated oligosaccharide chains in viral 
hosts are quite diverse. 
METhODS FOR DETERMINATION OF NA ACTIVITY
One of the most popular substrates for nA activity determi-
nation is Mu-neu5Ac or Mu-nAnA (Fig. 3a). the method 
based on the use of this substrate was proposed [36] first as 
an alternative to colorimetric or radioactive methods. Af-
ter cleavage of the neuraminic acid, Mu-neu5Ac forms a 
fluorophore which is activated by light at a wavelength of 
360 nm, and its fluorescence maximum is achieved at pH 
10. the closest analog of Mu-neu5Ac is the 4-trifluoro-
methylumbelliferyl-α-D-n-acetylneuraminic acid, whose 
fluorescence maximum is located in the neutral pH range. 
High fluorescence intensity (10-fold higher than for Mu-
neu5Ac) is useful in studies of low-activity neuraminidases 
[37]. 
the sensitivity of the chemiluminescent method of nA 
activity determination [38] is by a factor of 100 higher than 
that of Mu-neu5Ac-assay, and «nА-Star» is used as a sub-
strate (Fig. 3b). the main disadvantage of this method is the 
short lifetime of the product of chemiluminescent hydrolysis, 
which has to be recorded within 5 minutes.
the other group of methods is based on cleavage of the 
neuraminic acid from high molecular weight substrates, such 
as fetuin, the α1-acid glycoprotein or whole erythrocytes. the 
amount of free neuraminic acid is usually determined after 
cleavage [39]; the most convenient procedure for assay of 
neu5Ac allows for conducting measurements in the presence 
of the sialylated substrate [40].
An alternative procedure is based on assay of the second 
product of the hydrolysis, the desialylated glycoprotein, with 
the help of lectin (for example, Peanut agglutinin), which is 
specific for the unmasked terminal galactose [41, 42]. carry-
ing on with this analytical procedure requires great accuracy 
in control preparation, as every glycoprotein originally has 
terminal β-Gal residues.
METhODS FOR DETERMINATION OF 
NA SuBSTRATE SPECIFICITY 
the substrate specificity of nA is its ability to discriminate 
between sialic acids (for example, neu5Ac and neu5Gc) and 
linkage type with the next residue (2-3, 2-6 or 2-8), as well as 
the ability to identify internal regions of the oligosaccharide 
chain. In particular, the following structures have been used 
for the determination of nA substrate specificity:
•   free trisaccharides (3` SiaLac or 6`SiaLac) [43 - 45];
•   glycoproteins containing only 2-3, or only 2-6-linked neu-
raminic acid [45, 46];
•   glycoproteins or erythrocytes oversialylated with the aid of 
2-3- or 2-6- sialyltransferases [47].
Methods based on the use of those substrates achieve only 
one of the listed goals; in particular, they allow to study spe-
cificity at the level of Sia2-3Gal or Sia2-6Gal. More broad 
specificity can be studied with the use of an analytical proce-
dure which employs a number of synthetic substrates. In [42], 
a panel of three oligosaccharides was used: 3’SiaLac, 6’SiaLac 
and 6’SiaLacnAc, in the form of polyacrylamide conjugates; 
and neuraminidase activity was measured by lectin, specific 
for galactose residues, which appear as the result of nA ac-
tion (see above). A new simple and sensitive method for nA 
specificity determination has been developed recently [48]. It 
is based on the use of BODIPY-labeled sialyloligosaccarides. 
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the fluorescent label is covalently bound to the oligosaccha-
ride (3`SiaLac, 3`SiaLacnAc, SiaLec, SiaLea, SiaLex, 6`SiaLac, 
6`SiaLacnAc) via spacer, i.e. it is at some distance from the 
cleavage site. Stability, relative hydrophility, electroneutral-
ity, small size, and ability to use standard fluorescent filter 
for detection are the advantages of this label. the method 
is based on a quantitative separation of the electroneutral 
product of the reaction and the negatively charged substrate; 
separation is performed either on a microcartrige with an 
anion-exchange sorbent or microplates, the semipermeable 
bottom of which consists of an anion-exchange material. For 
greater reliability one may quantify the amount of the reac-
tion substrate, along with the quantity of the reaction prod-
uct. the high sensitivity of the method makes it possible to 
work with low substrate concentrations (10-11 mol), as well 
as with low virus concentrations. High accuracy (more than 
95%) and good reproducibility (98%) of the new method allow 
to study the kinetics of enzyme-substrate interactions. Stud-
ies of desialylation kinetics, in particular the reaction velocity 
and its dependence on substrate and enzyme concentration, is 
important for understanding the reaction mechanism, as well 
as for the choice of the correct concentration range. In turn, 
the correct range allows to study desialylation specificity in 
cases when the nA quantity in the test sample is unknown 
[49]. It is worth mentioning that only this approach allows to 
study many aspects of nA substrate specificity (see above), 
namely to study the influence of the sialic acid type, the type 
of linkage between the sialic acid and the next sugar, and the 
influence of the inner glycan sugars.
FuNCTIONAL FEATuRES OF SOME 
INFLuENzA VIRuS NEuRAMINIDASES 
As already mentioned above, high molecular weight sub-
strates, along with low molecular weight substrates, can be 
used for studying nA activity and specificity. Low molecular 
weight substrates allow to study the reaction mechanism and 
desialylation kinetics without the complications of multiva-
lent interactions (nA is a tetramer) and the possible influ-
ence of HA, which interacts with multivalent conjugate 3 – 5 
orders of magnitude better than with the monomeric one [50]. 
High molecular weight substrates appear to be a more ac-
curate model for studying natural interactions; that is when 
there is a necessity to account the nA tetrameric organiza-
tion, the clustering of nA molecules on the cell surface, and 
the involvement of the second surface glycoprotein, HA, 
which is present on the viral surface in larger amount. 
Investigation of the evolution of the influenza virus nA 
substrate specificity for viruses isolated from humans, and its 
comparison with the substrate specificity of influenza virus 
nAs isolated from different hosts, such as ducks and pigs, is 
of great importance. the first undertaking could shed light 
on the question of the unique character of pandemic strains, 
while the second could help detect in advance the properties 
of the enzyme which facilitate the crossing of the interspecies 
barrier.
the specificity of n2 subtype nA of human influenza vi-
ruses has gradually changed from 3’SiaLac (H2n2 strains iso-
lated in 1957) to dual specificity, 3`SiaLac/6`SiaLac (strains 
from 1972 to 1987). Hydrolytic activity towards 6’SiaLac was 
identified only for viruses isolated in 1967 and further, and 
starting from 1972 isolates an increase of activity towards this 
substrate was registered [46]. 
It has been shown recently that n2 influenza viruses are 
highly active towards 3’SiaLac, while their activity towards 
6’SiaLac varies from extremely low (avian and early human 
isolates) to high (swine and latter human isolates). It has been 
shown that nA activity towards 6’SiaLac depends also on 
the host type and, for human viruses, on the year of isolation 
[45].
For n1 strains isolated in the 70-80s [43, 44], it was shown 
that their neuraminidase equally recognizes 3’SiaLac and 
6’SiaLac.
Data on the substrate specificity of n1 and the n2 nAs 
of several duck, swine and human influenza virus isolates 
were obtained with the use of BODIPY-labeled synthetic 
oligosaccharides [48 - 51]. All of the studied nAs desialy-
lated α2-3-substrates better then α2-6 ones. In the case of 
viruses with n1 neuraminidase, α2-3/α2-6 activity factor 
was ~60 for duck viruses, ~20 for swine viruses, and ~4 for 
human viruses. In case of H9n2 influenza viruses, similar 
α2-3/α2-6 relations were found for the duck virus, whereas 
this relation for viruses isolated from poultry is in a range 
from 30 to 15, and for swine virus ~6, finally, for human iso-
(а) (b)
HO
HO
OH
NH
CH3
H3C
OH
HO
O
O
O O O O
HO OH OH
NH
Cl Cl
H3C
MeO
HO
HO
O
O
O
O
O O
Figure 3. Structure of MU-Neu5Ac (а) and NA-Star (b)
Enzyme
Enzyme
Enzyme
Enzyme Enzyme
Enzyme
HOR
hO
hO
hO
hO
hO
hO
hO
hO
hO
OR
Oh
Oh
OH
Oh
OH
Nh
Nh
Nh
N
N
N
N
N
N
N N
N
N
N N
H
H
H
H
H
O
O
O
O
O
O
O
O
O
O
O O
-
O
-
O
-
Scheme 1. Mecha-
nism of substrate 
desialylation by influ-
enza virus neurami-
nidase (according to 
[7], [15], and [16].) reVIeWS
 № 2 2009  | ActA nAturAe | 31
late ~10. For all the studied nA, it has been shown that they 
discriminate the fine structure of α2-3-substrates, that is 
they discriminate between the structures of the inner parts 
of oligosaccharides. 
With the use of the polyacrylamide conjugates of 3`SiaLac, 
6`SiaLac and 6`SiaLacnAc, it has been shown that most of the 
viruses (H1n1 and H3n2 subtypes) propagated on embryo-
nated chicken eggs and MDcK cells, preferably hydrolyze 
3’SiaLac, whereas VerO-isolates of the same viruses pref-
erably hydrolyze 6’SiaLacnAc. In summary, the nature of 
the host cell line used for virus accumulation influences nA 
substrate specificity [42]. the reason for this effect remains 
unknown.
It is difficult to compare the results of substrate specificity 
studies conducted by different authors due to the use of both 
different influenza virus strains and different substrates in 
varying concentrations. For example, the Kobasa [45] group 
has shown that maximum nA activity towards 6’SiaLac does 
not exceed the activity towards 3’SiaLac, whereas in the 
work of Baum & Paulson [46], this activity was much higher 
for the same viruses. It is also worth mentioning that studies 
of the influenza virus with the simultaneous use of high- and 
low-molecular weight substrates of a defined structure have 
yet to be conducted. 
Despite the limited amount of data published to date, it 
is already possible to discuss some features. Firstly, the nA 
substrate specificity of human isolates differs from that of 
avian isolates. Secondly, the oligosaccharide specificity of the 
nA of viruses which circulate in different hosts (birds, pigs, 
humans) notably differs, at least for the characteristic “ratio 
of the hydrolysis velocity of 2-3 oligosaccharides towards 2-6 
oligosaccharides.” thirdly, the substrate specificity of influ-
enza virus neuraminidases propagated on different cell lines 
may be different. 
Data on nA functioning would be incomplete without tak-
ing into account another surface protein of the influenza vi-
rus, haemagglutinin. there is only a limited number of pub-
lications describing the simultaneous study of HA and nA 
substrate specificity, and there is virtually no research where 
the dependence of HA and nA oligosaccharide specificity on 
one hand and virus infectivity on another hand have been 
studied. the state-of-the-art analytical procedures for nA 
introduced in the current review are now up to par with the 
more advanced analytical methods of HA analysis, which al-
ways developed faster; therefore, it is quite easy to predict 
that one of the main trends in influenza virus studies in the 
future would be joint studies of HA and nA specificity. 
This review was supported by RFBR grant 04-04-49669 and 
RAS Presidium Program ‘Molecular and Cell Biology’.
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